Vor Systems announced it secured $3 million in pre-seed financing to support the development of its AI-enabled transaction ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Vor Biopharma Inc. (NASDAQ:VOR) shares are trading higher on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing ...

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsJean-Paul Kress - Chairman ...

BOSTON--(BUSINESS WIRE)--Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, today announced a $42 ...

New data from Vor Bio show that its hematopoietic stem cells have, so far, successfully engrafted in the first seven patients with relapsed or refractory acute myeloid leukemia and that the new cells ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...